Feasibility of the administration of chemotherapy using cisplatin plus etoposide for non-small cell lung cancer patients with interstitial lung disease on chest computed tomography

PE treatment for unresectable NSCLC patients with ILD in our series was considered to be relatively safe, with an acceptable tumor response and survival. Obviously, careful patient selection and management are warranted. A prospective evaluation should also be performed.